Candel Therapeutics (CADL) Equity Average: 2021-2023
Historic Equity Average for Candel Therapeutics (CADL) over the last 2 years, with Sep 2023 value amounting to $26.9 million.
- Candel Therapeutics' Equity Average fell 52.06% to $26.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $26.9 million, marking a year-over-year decrease of 52.06%. This contributed to the annual value of $55.9 million for FY2022, which is 175.66% up from last year.
- According to the latest figures from Q3 2023, Candel Therapeutics' Equity Average is $26.9 million, which was down 23.61% from $35.2 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Equity Average ranged from a high of $63.9 million in Q1 2022 and a low of $9.9 million during Q3 2021.
- For the 3-year period, Candel Therapeutics' Equity Average averaged around $45.7 million, with its median value being $49.9 million (2022).
- In the last 5 years, Candel Therapeutics' Equity Average spiked by 466.32% in 2022 and then tumbled by 52.06% in 2023.
- Over the past 3 years, Candel Therapeutics' Equity Average (Quarterly) stood at $63.6 million in 2021, then fell by 21.46% to $49.9 million in 2022, then slumped by 52.06% to $26.9 million in 2023.
- Its Equity Average was $26.9 million in Q3 2023, compared to $35.2 million in Q2 2023 and $43.7 million in Q1 2023.